Lele Xu

Lele Xu

Auto-generated profile, based on publicly available information

Lele Xu

Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
LXLele Xu
Lele Xu
WLWen-Zhong Liu
Wen-Zhong Liu
TLTongtong Li
Tongtong Li
YHYuying Hu
Yuying Hu
YWYu Wang
Yu Wang
QZQimin Zhan
Qimin Zhan

14 July 2024 in iScience
Verified
Journal Article
Open access
LXLele Xu
Lele Xu
YCYuting Chen
Yuting Chen
TWTao Wu
Tao Wu
JFJiaqi Fan
Jiaqi Fan
YHYuying Hu
Yuying Hu
DWDinglan Wu
Dinglan Wu
Polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) represent a promising novel treatment for castration-resistant prostate cancer (CRPC) with encouraging results. However, the combination targets in CRPC remain largely unexplored. N6-methyladenosine (m6A) has been shown to play a crucial role in cancer progression and DNA damage response. Here, we observed a higher overall level of m6A and a downregulation of Fat mass and obesity-associated protein (FTO), which correlated with unfavorable clinicopathological parameters in prostate cancer (PCa). Functionally, reduced FTO promotes PCa growth, while overexpression of FTO has the opposite effect. Mechanistically, FOXO3a was identified as the downstream target of FTO in PCa. FTO downregulates the expression of FOXO3a in an m6A-dependent manner, leading to the degradation of its mRNA. Importantly, DNA damage can degrade FTO through the ubiquitination pathway. Finally, we found that overexpression of FTO can enhance the effect of PARPi on PCa. Therefore, our findings may provide insight into novel therapeutic approaches for CRPC.